| Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer A Montoya, CN Amaya, A Belmont, N Diab, R Trevino, G Villanueva, ... Oncotarget 8 (4), 6446, 2017 | 122 | 2017 |
| Epithelial-mesenchymal transition markers in breast cancer and pathological responseafter neoadjuvant chemotherapy S Elzamly, N Badri, O Padilla, AK Dwivedi, LA Alvarado, M Hamilton, ... Breast cancer: basic and clinical research 12, 1178223418788074, 2018 | 52 | 2018 |
| Disparities in breast cancer: a multi‐institutional comparative analysis focusing on American Hispanics Z Nahleh, S Otoukesh, HR Mirshahidi, AL Nguyen, G Nagaraj, G Botrus, ... Cancer medicine 7 (6), 2710-2717, 2018 | 33 | 2018 |
| Clinico-pathologic disparities of breast cancer in Hispanic/Latina women Z Nahleh, G Botrus, A Dwivedi, N Badri, S Otoukesh, N Diab, S Biswas, ... Breast Disease 37 (3), 147-154, 2018 | 13 | 2018 |
| Seronegative neuromyelitis optica: a case report of a hispanic male N Badri, M Teleb, S Syed, M Wardi, M Porres-Aguilar, S Cruz-Flores Case Reports in Neurology 8 (2), 102-107, 2016 | 8 | 2016 |
| Prevalence of low vitamin D in patients with breast cancer in a predominantly hispanic population at the American-Mexican border SE Farrag, AK Dwivedi, S Otoukesh, NJ Badri, LA Sanchez, ZA Nahleh Nutrition and cancer 69 (6), 819-824, 2017 | 5 | 2017 |
| Diffuse large B-cell non-Hodgkin's lymphoma and osteosclerotic myeloma with features of POEMS syndrome KS Ngamdu, A Torabi, N Badri, M Teleb, S Gaur Baylor University Medical Center Proceedings 29 (3), 306-308, 2016 | 4 | 2016 |
| Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma N Badri, KS Ngamdu, A Torabi, S Guar Journal of cancer research and therapeutics 16 (1), 183-185, 2020 | 3 | 2020 |
| Use of nonselective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget. 2017; 8: 6446–60 A Montoya, CN Amaya, A Belmont, N Diab, R Trevino, G Villanueva, ... | 3 | |
| A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update. C Yin, J Marshall, L Macke, K Bouker, AR He, BA Weinberg, LM Weiner, ... Journal of Clinical Oncology 40 (4_suppl), 581-581, 2022 | 2 | 2022 |
| Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study. RF Dunne, N Badri, M Nicolais, MS Noel, AM Baran, W Wang, ... Journal of Clinical Oncology 40 (4_suppl), 327-327, 2022 | 1 | 2022 |
| Evaluating end-of-life (EOL) care at the University of Rochester Medical Center (URMC) using quality oncology practice initiative (QOPI) metrics. T Banerjee, JH Mendler, N Badri, D Hettler, JA Berkhof, KJ Abbas, ... Journal of Clinical Oncology 37 (27_suppl), 12-12, 2019 | 1 | 2019 |
| Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study. J Zhao, G Gim, AM Baran, W Wang, J Zittel, AF Hezel, EE Ramsdale, ... Journal of Clinical Oncology 42 (3_suppl), 122-122, 2024 | | 2024 |
| Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial. N Badri, J Zittel, AM Baran, E Dotan, JM Hubbard, MS Noel, AF Hezel, ... Journal of Clinical Oncology 41 (16_suppl), 12047-12047, 2023 | | 2023 |
| Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy G Gim, N Badri | | 2023 |
| Abstract PO033: A phase 1b/2 trial of PXS-5505 combined with first line atezolizumab plus bevacizumab for treating patients with unresectable or metastatic hepatocellular carcinoma PR Burchard, LI Ruffolo, N Ullman, Y Dave, BA Belt, DC Linehan, ... Clinical Cancer Research 28 (17_Supplement), PO033-PO033, 2022 | | 2022 |
| Abstract PO024: Combination therapy with PXS-5505 improves chemotherapeutic efficacy and reduces myeloid immune suppression in murine cholangiocarcinoma–a novel therapeutic … PR Burchard, LI Ruffolo, NA Ullman, Y Dave, B Dale, M Georger, R Jewell, ... Clinical Cancer Research 28 (17_Supplement), PO024-PO024, 2022 | | 2022 |
| Abstract P6-10-04:“Disparities in breast cancer: A multi-institutional comparative analysis focusing on American Hispanics” S Otoukesh, Z Nahleh, HR Mirshahidi, AL Nguyen, G Botrus, N Badri, ... Cancer Research 78 (4_Supplement), P6-10-04-P6-10-04, 2018 | | 2018 |
| Varicella Pneumonia in Immunocompetent Male: A Case Report N Badri, M Teleb, S Ngamdu, A Albaghdadi, S Nagy Gen Med (Los Angeles) 5 (288), 2, 2017 | | 2017 |
| Prevalence of low vitamin D in patients with breast cancer in a predominantly Hispanic population at the American Mexican border. S Farrag, AK Dwivedi, S Otoukesh, N Badri, L Sanchez, ZA Nahleh Journal of Clinical Oncology 34 (15_suppl), e12051-e12051, 2016 | | 2016 |
